Does the media favor ACHV or INVA?

In the previous week, Innoviva had 12 more articles in the media than Achieve Life Sciences. MarketBeat recorded 16 mentions for Innoviva and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat Innoviva's score of -0.31 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACHV or NVAX?

In the previous week, Novavax had 5 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Novavax and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat Novavax's score of -0.07 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novavax 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ACHV or ZBIO more profitable?

Zenas BioPharma's return on equity of -99.99% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -193.49% -111.88% Zenas BioPharma N/A -99.99% -58.06%

Does the media prefer ACHV or ZBIO?

In the previous week, Achieve Life Sciences and Achieve Life Sciences both had 4 articles in the media. Zenas BioPharma's average media sentiment score of 0.75 beat Achieve Life Sciences' score of 0.23 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACHV or MNKD?

In the previous week, MannKind had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 5 mentions for MannKind and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat MannKind's score of 0.14 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OPK or ACHV?

In the previous week, Achieve Life Sciences had 1 more articles in the media than OPKO Health. MarketBeat recorded 4 mentions for Achieve Life Sciences and 3 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.69 beat Achieve Life Sciences' score of 0.23 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Achieve Life Sciences (ACHV) Competitors

$6.23 +0.21 (+3.49%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$6.18 -0.05 (-0.75%)

As of 06/29/2026 07:55 PM Eastern

Compare

ACHV vs. INVA, NVAX, ZBIO, MNKD, and OPK

Should you buy Achieve Life Sciences stock or one of its competitors? MarketBeat compares Achieve Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Achieve Life Sciences include Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Achieve Life Sciences compare to Innoviva?

Achieve Life Sciences (NASDAQ:ACHV) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Innoviva has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Innoviva	$420.69M	4.06	$271.17M	$6.01	3.85

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Achieve Life Sciences has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Innoviva had 12 more articles in the media than Achieve Life Sciences. MarketBeat recorded 16 mentions for Innoviva and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat Innoviva's score of -0.31 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Achieve Life Sciences presently has a consensus target price of $16.00, indicating a potential upside of 156.82%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 56.44%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has a net margin of 119.89% compared to Achieve Life Sciences' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Novavax?

Achieve Life Sciences (NASDAQ:ACHV) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Achieve Life Sciences presently has a consensus target price of $16.00, suggesting a potential upside of 156.82%. Novavax has a consensus target price of $13.00, suggesting a potential upside of 38.89%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has higher revenue and earnings than Achieve Life Sciences. Novavax is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A

Achieve Life Sciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

In the previous week, Novavax had 5 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Novavax and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat Novavax's score of -0.07 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Achieve Life Sciences has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Novavax	-14.73%	-14.82%	1.23%

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novavax beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Zenas BioPharma?

Achieve Life Sciences (NASDAQ:ACHV) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Zenas BioPharma's return on equity of -99.99% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Zenas BioPharma	N/A	-99.99%	-58.06%

Achieve Life Sciences has higher earnings, but lower revenue than Zenas BioPharma. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Zenas BioPharma	$10M	161.30	-$377.74M	-$8.47	N/A

Achieve Life Sciences has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Achieve Life Sciences presently has a consensus price target of $16.00, indicating a potential upside of 156.82%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 73.33%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Achieve Life Sciences is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Achieve Life Sciences and Achieve Life Sciences both had 4 articles in the media. Zenas BioPharma's average media sentiment score of 0.75 beat Achieve Life Sciences' score of 0.23 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Achieve Life Sciences and Zenas BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Achieve Life Sciences compare to MannKind?

Achieve Life Sciences (NASDAQ:ACHV) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Achieve Life Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Achieve Life Sciences presently has a consensus price target of $16.00, suggesting a potential upside of 156.82%. MannKind has a consensus price target of $8.97, suggesting a potential upside of 111.53%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Achieve Life Sciences is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MannKind had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 5 mentions for MannKind and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.23 beat MannKind's score of 0.14 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has higher revenue and earnings than Achieve Life Sciences. MannKind is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
MannKind	$348.97M	3.75	$5.86M	-$0.07	N/A

Achieve Life Sciences has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
MannKind	-6.63%	-11.21%	-3.92%

Summary

MannKind beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Achieve Life Sciences has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.88	-$225.68M	-$0.27	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

In the previous week, Achieve Life Sciences had 1 more articles in the media than OPKO Health. MarketBeat recorded 4 mentions for Achieve Life Sciences and 3 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.69 beat Achieve Life Sciences' score of 0.23 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 44.7% of OPKO Health shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

OPKO Health has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Achieve Life Sciences	N/A	-193.49%	-111.88%

OPKO Health currently has a consensus target price of $1.55, suggesting a potential upside of 2.65%. Achieve Life Sciences has a consensus target price of $16.00, suggesting a potential upside of 156.82%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Achieve Life Sciences beats OPKO Health on 9 of the 16 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$618.01M	$3.02B	$6.84B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-5.56	19.67	26.02	24.37
Price / Sales	N/A	338.20	549.39	102.32
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	15.58	4.25	10.98	6.49
Net Income	-$54.65M	$64.45M	$3.57B	$336.61M
7 Day Performance	24.35%	3.73%	2.60%	1.25%
1 Month Performance	18.89%	4.01%	0.93%	0.24%
1 Year Performance	175.66%	34.35%	36.40%	30.16%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	2.7836 of 5 stars	$6.23 +3.5%	$16.00 +156.8%	+179.4%	$618.01M	N/A	N/A	20
INVA Innoviva	3.2081 of 5 stars	$22.67 +0.8%	$36.20 +59.7%	+15.9%	$1.66B	$411.33M	3.77	100	News Coverage
NVAX Novavax	1.766 of 5 stars	$9.00 -1.4%	$13.00 +44.4%	+46.9%	$1.50B	$1.12B	N/A	1,990
ZBIO Zenas BioPharma	3.619 of 5 stars	$20.80 +5.2%	$44.29 +112.9%	+166.7%	$1.25B	N/A	N/A	N/A	Analyst Upgrade Gap Up
MNKD MannKind	2.872 of 5 stars	$3.89 -1.3%	$8.97 +130.6%	+12.8%	$1.22B	$348.97M	N/A	400	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. INVA, NVAX, ZBIO, MNKD, and OPK

How does Achieve Life Sciences compare to Innoviva?

Summary

How does Achieve Life Sciences compare to Novavax?

Summary

How does Achieve Life Sciences compare to Zenas BioPharma?

Summary

How does Achieve Life Sciences compare to MannKind?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. INVA, NVAX, ZBIO, MNKD, and OPK

How does Achieve Life Sciences compare to Innoviva?

Which has preferable valuation and earnings, ACHV or INVA?

Do insiders & institutionals believe in ACHV or INVA?

Which has more volatility and risk, ACHV or INVA?

Does the media favor ACHV or INVA?

Do analysts recommend ACHV or INVA?

Is ACHV or INVA more profitable?

Summary

How does Achieve Life Sciences compare to Novavax?

Do analysts rate ACHV or NVAX?

Which has stronger earnings & valuation, ACHV or NVAX?

Which has more volatility and risk, ACHV or NVAX?

Does the media favor ACHV or NVAX?

Is ACHV or NVAX more profitable?

Do insiders and institutionals have more ownership in ACHV or NVAX?

Summary

How does Achieve Life Sciences compare to Zenas BioPharma?

Is ACHV or ZBIO more profitable?

Which has higher valuation and earnings, ACHV or ZBIO?

Which has more volatility and risk, ACHV or ZBIO?

Do insiders & institutionals have more ownership in ACHV or ZBIO?

Do analysts rate ACHV or ZBIO?

Does the media prefer ACHV or ZBIO?

Summary

How does Achieve Life Sciences compare to MannKind?

Which has more risk & volatility, ACHV or MNKD?

Do analysts prefer ACHV or MNKD?

Do insiders and institutionals hold more shares of ACHV or MNKD?

Does the media refer more to ACHV or MNKD?

Which has higher earnings & valuation, ACHV or MNKD?

Is ACHV or MNKD more profitable?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Which has stronger earnings and valuation, OPK or ACHV?

Does the media favor OPK or ACHV?

Do institutionals and insiders have more ownership in OPK or ACHV?

Which has more risk & volatility, OPK or ACHV?

Is OPK or ACHV more profitable?

Do analysts recommend OPK or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools